Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meta-Analyses Will Get Separate Guidance Documents From FDA And IoM

Executive Summary

The question of how to develop meta-analyses of clinical trials that can yield useful information on drug and biologic safety will be the subject of an FDA guidance and an important focus of two reports from the Institute of Medicine

You may also be interested in...



Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible

To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.

Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible

To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.

FDA Seeks Dedicated Meta-Analysis Team As Part Of PDUFA V User Fee Funding

FDA wants to create a meta-analysis team to conduct its own studies with funding from the next round of application user fees.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel